PharmaCyte Biotech, Inc. financial data

Symbol
PMCB on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
23046 Avenida De La Carlota, Suite 600, Laguna Hills, CA
State of incorporation
NV
Fiscal year end
April 30
Former names
NUVILEX, INC. (to 1/9/2015), EFOODSAFETY COM INC (to 3/17/2009)
Latest financial report
10-Q - Q4 2024 - Mar 17, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 583 % -68.8%
Debt-to-equity 33.2 % -7.06%
Return On Equity 50.9 %
Return On Assets 35.4 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.86M shares -18.9%
Common Stock, Shares, Outstanding 6.9M shares -19%
Entity Public Float 18.2M USD -66.4%
Common Stock, Value, Issued 2.17K USD 0%
Weighted Average Number of Shares Outstanding, Basic 6.96M shares -19.1%
Weighted Average Number of Shares Outstanding, Diluted 6.96M shares -19.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 406K USD +1.69%
General and Administrative Expense 731K USD -66.9%
Operating Income (Loss) -6.5M USD -3.91%
Nonoperating Income (Expense) 26.8M USD +423%
Net Income (Loss) Attributable to Parent 20.3M USD -392%
Earnings Per Share, Basic 0.72 USD/shares +32.3%
Earnings Per Share, Diluted 0.72 USD/shares +32.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 16.4M USD -73.2%
Marketable Securities, Current 373K USD
Assets, Current 17M USD -72.4%
Intangible Assets, Net (Excluding Goodwill) 1.55M USD -56.3%
Assets 43.8M USD -38.6%
Accounts Payable, Current 485K USD +0.16%
Employee-related Liabilities, Current 135K USD -9.39%
Accrued Liabilities, Current 709K USD -8.39%
Liabilities, Current 1.19M USD -84.2%
Liabilities 3.58M USD -84.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -24.5K USD -6.12%
Retained Earnings (Accumulated Deficit) -96.7M USD +17.3%
Stockholders' Equity Attributable to Parent 40.3M USD +28.3%
Liabilities and Equity 43.8M USD -38.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -373K USD -209%
Net Cash Provided by (Used in) Financing Activities -10.2M USD -262%
Net Cash Provided by (Used in) Investing Activities -7M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 21.7M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -17.5M USD -365%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 16.4M USD -73.2%
Deferred Tax Assets, Valuation Allowance 15.2M USD -6.38%
Deferred Tax Assets, Gross 15.2M USD -6.38%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 20.3M USD -393%
Deferred Tax Assets, Operating Loss Carryforwards 14.4M USD -8.23%
Preferred Stock, Shares Issued 35K shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 181M USD -4.12%
Preferred Stock, Shares Outstanding 35K shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%